Home › Burkitt Lymphoma › Pennsylvania
Burkitt Lymphoma clinical trials in Pennsylvania
18 studies for Burkitt Lymphoma are looking for participants at sites in Pennsylvania.
Cities in Pennsylvania
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Penn State Children's Hospital, Hershey
- Children's Hospital of Philadelphia, Philadelphia
- and 2 more
RecruitingPhase 2
366 Days – 46 Years · All sexes · Updated Oct 2, 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- and 1 more
RecruitingPhase 3
Ages 18 to 39 · All sexes · Updated Oct 2, 2026 · NCT03150693Blinatumomab Consolidation in Real World
- University of Pennsylvania, Philadelphia
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07117136Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Philadelphia, Philadelphia
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 1, 2026 · NCT06131801Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- and 2 more
RecruitingPhase 2
365 Days · All sexes · Updated Sep 25, 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Penn State Hershey Medical Center, Hershey
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Children's Hospital of Philadelphia (Data Collection Only), Philadelphia
RecruitingPhase 3
Ages 1 and older · All sexes · Updated Sep 17, 2026 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia
RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1
Ages 0 to 18 · All sexes · Updated Sep 16, 2026 · NCT06173518A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- and 3 more
RecruitingPhase 2
Ages 1 to 30 · All sexes · Updated Sep 1, 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- and 3 more
RecruitingPhase 3
365 Days – 25 Years · All sexes · Updated Aug 25, 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 2
Ages 7 to 25 · All sexes · Updated Aug 19, 2026 · NCT05082519Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
- UPMC Hillman Cancer Center, Pittsburgh
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT07069699CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
- Children's Hospital of Philadelphia, Philadelphia
Recruiting
Up to age 25 · All sexes · Updated Jul 8, 2026 · NCT03810196Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1/2
Ages 0 to 29 · All sexes · Updated May 26, 2026 · NCT05480449Co-administration of CART22-65s and huCART19 for B-ALL
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1/2
Up to age 29 · All sexes · Updated Mar 27, 2026 · NCT05674175Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Children's Hospital of Philadelphia, Philadelphia
RecruitingPhase 1/2
Ages 15 to 50 · All sexes · Updated Sep 9, 2025 · NCT04150497Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
- AHN Cancer Institute - West Penn Hospital, Pittsburgh
RecruitingPhase 2
Ages 18 to 79 · All sexes · Updated Jan 13, 2025 · NCT05281809From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.